Phase 2 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand and voluntarily sign a written consent form
- Adults aged 18 years or older
- People who have been diagnosed with advanced solid tumour cancers, confirmed through laboratory testing of tissue or cell samples
- People whose tumours have been tested for HER2 expression (positive or negative); if HER2 status is unknown, it must be tested before joining; people with HER2-positive tumours must have previously received anti-HER2 treatment
- People whose tumour tissue or blood samples show overexpression and/or amplification of a protein called MET, as confirmed by the trial's central laboratory
- People who have at least one tumour lesion that can be measured or assessed according to standard imaging guidelines (called RECIST v1.1)
- People with a general health score of 0 or 1 on a standard scale used by doctors to measure how well a person can carry out daily activities (called ECOG Performance Status)
- People whose expected survival is at least 3 months
- People whose major organs and bone marrow are functioning at a level that meets the trial's requirements (confirm with trial site)
Who may not be able to join:
- People who have previously been treated with drugs that specifically target MET
- People who have previously received a chemotherapy drug called docetaxel
- People who have cancer that has spread to the membranes surrounding the brain, is compressing the spinal cord, or has spread to the brain with active or worsening symptoms
- People with a known allergy or intolerance to any ingredient in the study drugs
- People whose side effects from previous cancer treatments have not sufficiently resolved (confirm with trial site for specific grading details)
- People with severe or uncontrolled other medical conditions that could interfere with participation in the trial
- Women who are currently pregnant or breastfeeding; women who test positive on a pregnancy blood test within 7 days before joining the trial; women who are breastfeeding may only be considered if they stop breastfeeding and agree not to resume it during or after study treatment
- People of childbearing potential (male or female) who are unwilling to use a highly effective form of contraception throughout the trial and for 6 months after the last dose
- People who are unwilling or unable to follow the study procedures, or who the trial doctor considers unsuitable for participation
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-0311-69085587
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose escalation and cohort expansion phase: The occurrence and frequency of DLT (Dose-Limiting Toxicity); Dose escalation and cohort expansion phase: the occurrence and frequency of AE (Adverse Events) and SAE (Serious Adverse Events) (in accordance with NCI-CTCAE 5.0); Dose escalation and cohort expansion phase: Recommended Phase 2 Dose (RP2D) for the combination therapy.; Proof-of-concept phase: Objective Response Rate (ORR) evaluated by the Independent Review Committee (IRC) according to the RECIST 1.1 criteria.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.